HC Wainwright Has Positive Estimate for ACXP Q3 Earnings

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Acurx Pharmaceuticals in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst M. Keller now expects that the company will earn ($0.45) per share for the quarter, up from their prior estimate of ($0.48). The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.00) EPS and FY2027 earnings at ($1.60) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.15).

A number of other analysts have also weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Stock Up 18.3%

ACXP opened at $1.65 on Tuesday. The business has a fifty day moving average of $1.52 and a 200 day moving average of $2.19. Acurx Pharmaceuticals has a 52-week low of $1.31 and a 52-week high of $8.34. The stock has a market cap of $7.09 million, a P/E ratio of -0.61 and a beta of -2.03.

Institutional Trading of Acurx Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC bought a new stake in shares of Acurx Pharmaceuticals during the second quarter valued at approximately $551,000. Millennium Management LLC bought a new position in Acurx Pharmaceuticals in the fourth quarter worth approximately $103,000. Geode Capital Management LLC purchased a new position in Acurx Pharmaceuticals during the 4th quarter worth $31,000. Finally, Jane Street Group LLC purchased a new position in Acurx Pharmaceuticals during the 4th quarter worth $27,000. Institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).